Related Experiment Video
Updated: Mar 8, 2026
05:32
A Detailed Protocol for Perspiration Monitoring Using a Novel, Small, Wireless Device
Published on: November 24, 2016
8.3K
Initial study of transdermal oxybutynin for treating hyperhidrosis.
José Francisco Millán-Cayetano1,2, Javier Del Boz1, Tomas Toledo-Pastrana3
1Dermatology Department, Hospital Costa del Sol, Marbella, Málaga, Spain.
The Journal of Dermatology
|January 21, 2017
Summary
Transdermal oxybutynin may offer a well-tolerated alternative for hyperhidrosis treatment. However, its effectiveness appears limited, particularly for patients previously treated with oral oxybutynin.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Oral oxybutynin is effective for hyperhidrosis but causes frequent mild side effects.
- Transdermal oxybutynin is explored as a potentially better-tolerated alternative.
Purpose of the Study:
- To evaluate the effectiveness and safety of transdermal oxybutynin for hyperhidrosis.
- To compare outcomes in patients previously treated versus untreated with oral oxybutynin.
Main Methods:
- Prospective study conducted in 2015.
- Included 7 previously treated and 6 untreated patients.
- Assessed effectiveness using the Hyperhidrosis Disease Severity Scale and tolerance over 12 months.
Main Results:
- High discontinuation rates due to ineffectiveness or local irritation in previously treated patients.
- Among untreated patients, 4/6 showed improvement, but all discontinued treatment within 12 months.
- No major adverse effects were observed; transdermal form lacks active metabolites.
Conclusions:
- Transdermal oxybutynin may have limited effectiveness for hyperhidrosis, especially in patients intolerant to oral forms.
- It might be a viable option for treatment-naïve patients, offering good tolerance.
- Further research is needed to clarify its role in hyperhidrosis management.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
80
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
80
01:23Ophthalmic Drug Delivery Systems
126
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
126
01:26Oral Drug Delivery Systems: Continuous-Release Systems
110
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
110
01:26Cholinergic Antagonists: Therapeutic Uses
1.6K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.6K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
818
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
818
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K